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At discharge from rehabilitation, stroke survivors may only 
walk at 0.55 m/s, well below normal (1.2-1.4 m/s) and not 
even fast enough to cross a road before the pedestrian cross-
ing lights change (0.8 m/s).1 Consequently, improving 
walking recovery is an important goal.2 Clinical guidelines 
recommend repetitive functional task training (eg, 
Donaldson et al3), but if stroke survivors have substantial 
weakness, such training presents a challenge.
An ankle-foot orthosis (AFO) positions the foot in rela-
tion to the lower leg to optimize normal alignment during 
gait and thus improve walking performance.4 The optimal 
type of AFO is considered to be a device customized for 
individuals by an orthotist.4 Obtaining this within an appro-
priate timescale early after stroke can be problematic in 
clinical practice.4 The device evaluated here was a SWIFT 
Cast, custom-made and fitted by a therapist within 24 hours. 
This trial was focused on the potential use of a SWIFT Cast 
to provide optimal alignment of the lower limb to the 
ground during walking. The specific aim was to begin test-
ing the hypothesis that the use of a SWIFT Cast, provided 
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Abstract
Background. Timely provision of an ankle-foot orthosis (AFO) orthotist customized for individuals early after stroke can 
be problematic. Objective. To evaluate the efficacy of a therapist-made AFO (SWIFT Cast) for walking recovery. Methods. 
This was a randomized controlled, observer-blind trial. Participants (n = 105) were recruited 3 to 42 days poststroke. 
All received conventional physical therapy (CPT) that included use of “off-the-shelf” and orthotist-made AFOs. People 
allocated to the experimental group also received a SWIFT Cast for up to 6 weeks. Measures were undertaken before 
randomization, 6 weeks thereafter (outcome), and at 6 months after stroke (follow-up). The primary measure was walking 
speed. Clinical efficacy evaluation used analysis of covariance. Results. Use of a SWIFT Cast during CPT sessions was 
significantly higher (P < .001) for the SWIFT Cast (55%) than the CPT group (3%). The CPT group used an AFO in 26% of 
CPT sessions, compared with 11% for the SWIFT Cast group (P = .005). At outcome, walking speed was 0.42 (standard 
deviation [SD] = 0.37) m/s for the CPT group and 0.32 (SD = 0.34) m/s for the SWIFT Cast group. Follow-up walking speed 
was 0.53 (SD = 0.38) m/s for the CPT group and 0.43 (0.34) m/s for the SWIFT Cast group. Differences, after accounting 
for minimization factors, were insignificant at outcome (P = .345) and follow-up (P = .360). Conclusion and implications. 
SWIFT Cast did not enhance the benefit of CPT, but the control group had greater use of another AFO. However, SWIFT 
Cast remains a clinical option because it is low cost and custom-made by therapists who can readily adapt it during the 
rehabilitation period.
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as an adjunct to conventional physical therapy (CPT), 
enhances walking recovery early after stroke more than 
CPT alone. This trial embedded mechanistic investigation 
of (a) the biomechanical correlates of walking improve-
ment in response to the 2 forms of therapy and (b) the 
potential use of baseline biomechanical characteristics and 
site of stroke lesion as prognostic indicators of response. 
Here we report the clinical efficacy investigation.5 The 
investigation of the potential indicators of beneficial 
response and the underlying mechanisms of response to 
both experimental and control therapies will be communi-
cated in additional reports.
Methods
Design
This study was a randomized, controlled, observer-blind 
phase II trial. All outcome measures were evaluated at the 
end of the 6-week intervention phase and at 6 months after 
stroke. Participants did not wear the SWIFT Cast while 
measures were evaluated. Into this clinical trial were 
embedded investigations of (a) the biomechanical corre-
lates of walking improvement in response to therapy and 
(b) potential use of baseline biomechanical characteristics 
and site of stroke lesion as prognostic indicators of 
response. The embedded biomechanical investigations 
used the same gait parameters used for the clinical effi-
cacy investigation reported here. The embedded stroke 
lesion site investigation involved structural neuroimaging 
undertaken 3 to 8 weeks after stroke onset. These embed-
ded investigations are to be reported in subsequent arti-
cles. The full protocol is as described in an earlier 
publication.5
Setting and Participants
Recruitment was from 2 stroke rehabilitation services. 
Participants were 18+ years old; 3 to 42 days poststroke 
(infarct or hemorrhage); fit for rehabilitation; able to take 3 
steps while supported by 2 people, but with (a) an abnormal 
initial floor contact and/or (b) impaired ability to take full 
body weight through the paretic lower limb in stance; had 
no contractures in, or loss of skin integrity over, the lower 
limb; and able to follow a 1-stage command.
Randomization
Group allocation was ordered pretrial by an independent 
statistician. Minimization was used with (a) ability to walk 
independently, as assessed by the Functional Ambulation 
Category (FAC; higher = 3-5 and lower = 2 or less)6; (b) 
clinical assessment of primary motor cortex involvement in 
the stroke lesion (yes/no); and (c) clinical center (A/B). An 
independent telephone randomization service concealed 
group allocation until after baseline measures.
Interventions
All participants received CPT (treatment as usual) that 
included interventions designed to enhance movement per-
formance and functional ability (supplementary material). 
The experimental group also received a customized SWIFT 
Cast (supplementary material). During CPT, the SWIFT 
Cast was worn for walking retraining, and participants were 
asked to wear the SWIFT Cast for the whole of their waking 
day initially. As gait improved, daily use was adjusted 
appropriately.
Splinting techniques, including AFOs, were used in both 
clinical centers.3 There were clinical concerns that if AFOs 
were not used in CPT, therapy would be suboptimal. The 
verbal agreement for this trial with the clinical therapists 
was that they would maintain their pretrial practice but that 
individuals allocated to the SWIFT Cast group would not 
receive another AFO during the intervention phase between 
baseline and outcome measurement time points (6 weeks). 
Research and clinical therapists met regularly and as needed 
throughout the trial to consider this. In addition, there were 
regular trial management meetings involving the research 
therapists, principle investigators, trial manager, and chief 
investigator. Influencing the routine interventions (CPT) 
provided by the clinical team was neither possible nor desir-
able. There are ethical and research governance frameworks 
that are designed to protect people from undue influence 
before and during their involvement in a trial.
Outcome Measures
The primary outcome measure was walking speed. Secondary 
outcome measures were the following: FAC,6 Modified 
Rivermead Mobility Index (MRMI),7 peak angular velocity 
of the knee,8 gait symmetry, and angle of the tibia with the 
ground during walking. Participants did not wear either a 
SWIFT Cast or AFO during conduction of measures. The 
rationale was that a SWIFT Cast was designed to enhance 
recovery of motor control for walking and not to compensate 
for its loss.
Sample Size
It was estimated that with a sample size of 110, the trial had 
80% power at 5% significance to detect a clinical improve-
ment of 0.13 m/s for walking speed with a standard devia-
tion (SD) of improvement of 0.24 m/s. With this sample 
size, a clinical improvement of 1.1 points on the FAC, 
assuming a SD of 2 points, could be detected. To allow for 
an attrition rate of approximately 10%, the target sample 
was 120 participants (60 in each group).
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Analyses
All participants were analyzed according to the group to which 
they were randomly allocated. The clinical efficacy analysis 
was carried out using analysis of covariance adjusting for the 
baseline values and any imbalance in factors between the 2 
groups. When the assumptions of analysis of covariance were 
not met, a P value and 95% confidence interval were estimated 
using a nonparametric bootstrap with 10 000 repetitions. All 
results were checked for sensitivity to missing data by imput-
ing the data using iterative chain equations.
The total amount of CPT received was compared between 
the 2 treatment groups. To account for the inherent noninde-
pendence of therapy sessions on the same individual, a ran-
dom-effects model was used, with participant as the random 
effect. Fixed effects were the factors used to stratify 
randomization.
Trial Oversight
A favorable ethical opinion was obtained from the National 
Research Ethics Service (reference 09/H0310/87). A Trial 
Steering Committee and a Data Monitoring Committee with 
independent chairs were convened. The Trial Steering 
Committee met 6 times and the Data Monitoring Committee 
4 times to ensure good conduct of the trial and safety of par-
ticipants and to monitor data collection. A Trial Management 
Group, including public and patient representatives, met 
regularly to monitor day-to-day running of the trial.
Serious Adverse Events




Between October 20, 2010, and December 6, 2012, 2287 
stroke survivors were screened (Figure 1). Of these, 2122 
were ineligible, and 60 declined. Accordingly, 105 partici-
pants underwent baseline assessments and then were allo-
cated randomly to either CPT (n = 54) or SWIFT Cast (n = 
51). Measures postintervention (outcome) were completed 
by 46 (90.2%) of the CPT and 45 (83.3%) of the SWIFT 
Cast group. At follow-up, the measures were completed by 
42 (77.8%) CPT and 36 (82.4%) SWIFT Cast participants. 
Reasons for attrition are shown in Figure 1.
Baseline Characteristics
Baseline characteristics were balanced across the groups 
(Table 1). In summary, participants were a mean (SD) of 
20.9 (19.0) days after stroke, with a mean age 66.7 (14.5) 
years. The right side of the body was more paretic for 50.4% 
of participants. For both groups, the mean walking speed 
was 0.1 (SD = 0.2) m/s and median FAC was 1.
Routine CPT Received
In total, 895 sessions of CPT were provided (Table 2 and 
supplementary material; 487 for SWIFT Cast and 408 for 
CPT). The median (IQR) number of CPT sessions was 10 
(0-16) for the SWIFT Cast and 7 (0-12) for the CPT group 
(P = .952). There were also no differences between the 
groups for the total duration of sessions (minutes) with 
median (IQR) values of 235 (0-590) and 140 (0-350) for the 
SWIFT Cast and CPT groups respectively (P = .792).
There were no intergroup differences for the aims of ther-
apy, gross positions of participants, or for 10 of the 11 spe-
cific interventions. As expected, there were significantly (P < 
.001) more sessions involving splinting techniques for the 
SWIFT Cast (n = 313; 64.9%) than for the CPT group (n = 
125; 31.4%) as a result of use of a SWIFT Cast. An AFO was 
used in more sessions (P = .005) for the CPT (n = 104; 26.1%) 
than for the SWIFT Cast group (n = 55; 11.4%). The number 
of individuals using an AFO in at least 1 CPT session was 9 
of 51 (17.6%) of the SWIFT Cast and 19 of 54 (35.2%) of the 
CPT group (P = .002).
Serious Adverse Events
No serious adverse events met the criteria for reporting to 
the National Research Ethics Service.
Primary Outcome
At the primary time point (outcome), the mean (SD) walking 
speed (m/s) was 0.42 (0.37) for the CPT and 0.32 (0.34) for 
the SWIFT Cast group (Table 3). At follow-up, walking 
speed (m/s) had increased further to 0.53 (0.38) for the CPT 
and 0.43 (0.34) for the SWIFT Cast group. The intergroup 
difference was not significant at outcome (P = .345) or fol-
low-up (P = .360).
Secondary Outcomes
At outcome (Tables 4 and 5), 65.1% of participants in the 
CPT and 61.3% of those in the SWIFT Cast group were able 
to walk 3 m independently compared with 24.1% and 19.6%, 
respectively, at baseline (Table 1). At follow-up, 75.7% of the 
CPT and 71.0% of the SWIFT Cast group were able to walk 
3 m independently. The intergroup differences were not sig-
nificant at outcome (P = .803) or at follow-up (P = .715).
At outcome, median FAC scores had improved to 4.0 
from a baseline of 1.0 in both groups. For MRMI, the 
improvements were from mean (SD) = 25.0 (8.4) to 33.95 
(5.95) for the CPT and from 23.4 (7.5) to 32.65 (7.51) for 
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the SWIFT Cast group. The intergroup differences were not 
statistically significant for either FAC (P = .822) or MRMI 
(P = .610). At follow-up, median FAC scores remained at 
4.0 for both groups. Further improvement was observed for 
MRMI at follow-up when the mean (SD) score for the CPT 
was 36.14 (5.11) and for the SWIFT Cast group was 35.75 
(4.30). The intergroup differences at follow-up were not 
significant for either FAC (P = .257) or MRMI (P = .969). 
There were no differences between groups for any other of 
the secondary outcomes at outcome or follow-up.
Discussion
The results suggest that a SWIFT Cast used as an adjunct to 
CPT might not enhance walking recovery early after stroke. 
However, the use of AFOs in the CPT group was higher than 
expected from pretrial observations and discussion with clin-
ical therapists. This potential confounder is discussed below. 
Considering the actual level of AFO use in the CPT group, 
the use of a SWIFT Cast early after stroke did not reduce 
recovery and, therefore, is possibly a clinical option for indi-
viduals early after stroke. Investigation of this possibility is 
Figure 1. CONSORT flowchart.
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warranted especially as a SWIFT Cast is different from an 
off-the-shelf or orthotist-made AFO. It is made from different 
materials, might have different properties, is custom-made by 
therapists who can readily adapt it during the rehabilitation 
period, and costs less (Condie et al4).
An obvious potential confounder in this trial is that sig-
nificantly more people in the control group (35.2%) used an 
AFO during the CPT sessions than those in the SWIFT Cast 
group (17.6%). Awareness that AFO provision was part of 
routine CPT prompted the procedure by which clinical ther-
apists agreed verbally to maintain their pretrial practice for 
the control group during the data collection period in con-
sideration of the clinical uncertainty principle and genuine 
equipoise. Moreover, in keeping with best research practice 
and as stated in the ethical application and information 
given to participants, it was important to minimize the 
influence of research on routine clinical practice. It was 
anticipated from pretrial observation, conversations with 
clinical therapists, and research evidence9 that AFOs were 
used infrequently. To monitor the use of AFOs throughout 
the data collection period, the clinical and research thera-
pists talked frequently. Despite these expectations and pre-
cautions, clinical provision of AFOs could be a confounding 
factor. Curiously, routine CPT also included use of a SWIFT 
Cast in 2.6% of the sessions provided for people in the con-
trol group, suggesting clerical error or that clinical thera-
pists were “trying out” devices. In one clinical center, we 
were aware that the use of AFOs in CPT had probably 
increased and that this was related to production of some 
clinical guidelines.10 Interestingly, the strength of research 
Table 1. 
Group
Participant Characteristics at Baseline.a CPT (n = 54) SWIFT Cast (n = 51)
Age (years) 64.2 (15.3) 69.1 (13.6)
Time since stroke (days) 19.5 (11.3) 22.2 (26.7)
Lanarkshire site 33 (61.1) 31 (60.8)
Male 37 (68.5) 26 (51.0)
Type of stroke
x Hemorrhage 8 (14.8) 8 (15.7)
x Infarct 45 (83.3) 41 (80.4)
x Missing 1 (1.9) 2 (3.9)
PMC involved in lesion 27 (50.0) 24 (47.1)
Right paretic side 29 (53.7) 24 (47.1)
FAC high categorization 15 (27.8) 10 (19.6)
FAC median 1 (0-3) 1 (0-2)
Walking speed (m/s) 0.1 (0.2) 0.1 (0.2)
MRMI total score 25 (8.4) 23.4 (7.5)
Peak knee velocity: nonparetic (degrees/s) 5.6 (10.2) 4.6 (9.4)
Peak knee velocity: paretic (degrees/s) 4.5 (8.4) 3.8 (8.2)
Able to walk 3 m independently
x No 40 (74.1) 40 (78.4)
x Yes 13 (24.1) 10 (19.6)
x Missing 1 (1.9) 1 (2.0)
Gait parameters (n = 23)
Tibial angle to vertical (degrees) at
x Initial contact −0.9 (8.8) −1.6 (8.7)
x Foot flat 3.2 (6.0) 4.4 (6.3)
x Midstance 10.6 (5.1) 10.6 (3.7)
x Heel rise 28.8 (3.9) 28.3 (4.5)
x Terminal contact 40.7 (5.2) 40.8 (5.4)
x Midswing 26.1 (7.0) 28.2 (4.3)
Ratio of stance times −0.1 (0.2) −0.1 (0.2)
Ratio of step lengths 0.0 (0.1) 0.0 (0.1)
Ratio of peak angular velocities −0.1 (0.1) 0.0 (0.1)
Abbreviations: CPT, conventional physical therapy; FAC, Functional Ambulation Category; MRMI, Modified Rivermead Mobility Index; SD, standard 
deviation; IQR, interquartile range; PMC, primary motor cortex.
aValues are mean (SD), median (IQR), or n (%).
 at University of Strathclyde on August 27, 2015nnr.sagepub.comDownloaded from 
6 Neurorehabilitation and Neural Repair 
evidence for the use of AFOs early after stroke did not 
increase from the pretrial situation. Indeed, the clinical 
guidelines recommendation used C-grade evidence for 
“where the aim of treatment is to have an immediate 
improvement on walking speed, efficiency or gait pattern or 
weight bearing during stance, patients should be assessed 
for suitability for an AFO by an appropriately qualified 
health professional.”10 Unfortunately, numerical data about 
AFO use during CPT sessions was only available to the trial 
team after hard-lock of the database. In both centers, it is 
possible that involvement in the trial increased clinical 
awareness of AFOs. With hindsight, it would have been 
beneficial to record use of AFOs in CPT before data collec-
tion began and to have applied to the ethical committee to 
enable us to undertake online monitoring of clinical prac-
tice and identify any variance from pretrial use of AFOs. 
Whether or not we would have been granted approval for 
such a request is unknown.
A systematic review identified only one previous ran-
domized trial investigating the use of an AFO/cast in the first 
3 months after stroke.11 Our systematic search did not iden-
tify any subsequent randomized trials. The earlier trial also 
found no difference in walking speed (effect size = 0.00 
[−0.08, 0.08])9,11 but did report a highly significant increase 
Table 3. Walking Speed (m/s; primary outcome) at Outcome and Follow-up.
CPT, Mean (SD) 
(Outcome, n = 45; 
Follow-up, n = 42)
SWIFT Cast, Mean 
(SD) (Outcome, n = 46; 
Follow-up, n = 36)
Effect Size  
(95% CI) P Value
Adjusted Effect 
Size (95% CI) P Value
Observed
 Outcome 0.42 (0.37) 0.32 (0.34) −0.06 (−0.20,0.07) .345 −0.06 (−0.19, 0.08) .350
 Follow-up 0.53 (0.38) 0.43 (0.34) −0.08 (−0.23, 0.09) .360 −0.08 (−0.24, 0.09) .315
Imputed
 Outcome −0.07 (−0.21, 0.08) .369 −0.07 (−0.21, 0.07) .340
 Follow-up −0.07 (−0.24, 0.11) .458 −0.07 (−0.24, 0.11) .430
Abbreviations: CPT, conventional physical therapy; SD, standard deviation; 95% CI, 95% confidence interval.
Table 2. Conventional Physical Therapy (CPT) Received by Both Groups and Use of Splinting Techniques in Centers.
Between-Group Comparison CPT (n = 54) SWIFT (n = 51) Odds Ratio (95% CIs) P Value
Number of sessions
 Total 408 487  
 Median (IQR) per participant 7 (0.12) 10 (0.16) .0952
Time duration (minutes)
 Total duration, median (IQR) 140 (0-350) 235 (0-590) .792
 Mean (SD) duration per participant session 33.23 (15.54) 39.06 (16.44) .289a
Splinting techniques used
 Number (percentage of total) of sessions involving 
splinting techniques
313 (64.9%) 125 (31.4%) 0.06 (0.02, 0.22) <.001
  Strapping, number (%) of sessions 13 (3.3%) 5 (1.0%) 6.53 (0.40, 106.60)b .188
  Ankle foot orthosis (AFO), number (%) 104 (26.1%) 55 (11.4%) 10.36 (1.99, 53.95) .005
  SWIFT Cast, number (%) 10 (2.6%) 264 (54.9%) 0.00 (0.00, 0.02) <.001
 Participants used AFO, at least 1 session, number 
(%)
19 (35.2%) 9 (17.6%) 0.31 (0.12,0.83) .020
 Participants used SWIFT Cast, at least 1 session, 
number (%)
7 (13%) 32 (62.8%) 12.64 (4.49, 35.58)  
Between-center comparison of sessions Centre A Centre B  
 Any splinting techniques, number (%) 272 of 538 166 of 342 0.89 (0.18, 4.36) .887
 Use of an AFO, number (%) 92 of 538 67 of 342 3.03 (0.39, 23.31)b .288
 (17.1%) (19.6%)  
Abbreviations: IQR, interquartile range; SD, standard deviation.
aEstimated from a random-effect linear regression model with participant as the random effect adjusting for factors used to stratify the randomization. 
To account for the nonnormality of the residuals a nonparametric bootstrap, with clustering variable as the participants, with 1000 repetitions, was 
used to estimate the P value and confidence interval.
bEstimated from a random-effect logistic regression model with participant as the random effect adjusting for factors used to stratify the randomization.
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Table 4. Secondary Measures at Outcome.a
CPT (n = 45)
SWIFT Cast  
(n = 46)
Effect Size  
(95% CI) P Value
Adjusted Effect 
Size (95% CI) P Value
FAC 4.0 (3.0-4.0) 4.0 (2.0-4.0) .822  
MRMI 33.93 (5.95) 32.65 (7.51) −0.69 (−3.38, 1.96) .610 −0.71 (−2.95, 1.58) .539
Peak knee velocity, nonparetic 
(degrees/s)b
24.58 (36.40) 27.75 (54.62) 4.22 (−13.12, 23.11) .647  
Peak knee velocity, paretic 
(degrees/s)b
21.93 (45.21) 19.60 (38.54) −1.29 (−19.61, 14.81) .884  
Able to walk 28/43c (65.12) 27/44c (61.36) 0.89 (0.37, 2.18) .803  
Tibial angle to vertical at
x Initial contact −8.26 (6.13) −6.83 (6.7) 1.10 (−2.10, 4.29) .494  
x Foot flat −1.16 (5.55) −1.35 (4.87) −0.55 (−3.35, 2.24) .692  
x Midstance 8.54 (5.33) 7.83 (4.52) −0.89 (−3.59, 1.81) .509  
x Heel rise 27.42 (5.43) 26.22 (6.13) −1.59 (−4.47, 1.28) .272  
x Terminal contact 40.59 (8.34) 38.14 (8.77) −2.62 (−6.93, 1.69) .228  
x Midswing 21.08 (8.39) 20.68 (8) −0.41 (−4.07, 3.24) .821  
Ratio of stance timesd −0.17 (0.19) −0.17 (0.16) .506  
Ratio of step lengthsd −0.02 (0.05) −0.03 (0.12) .264  
Ratio peak angular velocities 0 (0.11) −0.04 (0.18) .943  
Abbreviations: CPT, conventional physical therapy; FAC, Functional Ambulation Category; MRMI, Modified Rivermead Mobility Index; SD, standard 
deviation; IQR, interquartile range.
aValues are mean (SD), median (IQR), or number (%).
bBootstrap used because of nonnormality of residuals.
cMissing walking data for 2 participants.
dBased on Mann-Whitney test of absolute value treating those unable to walk as the largest values; mean (SD) refer only to those able to walk.
Table 5. Secondary Measures at Follow-up.a
CPT, Mean (SD), 
n = 42
SWIFT Cast, Mean 
(SD), n = 36
Effect Size  
(95% CI) P Value
Adjusted Effect 
Size (95% CI) P Value
FAC 4.00 (4.00-5.00) 4.00 (4.00-5.00) .257  
MRMI 36.14 (5.11) 35.74 (4.30) −0.04 (−2.01,1.84) .969 −0.16 (−1.95,1.66) .860
Peak knee velocity, 
nonparetic (degrees/s)b
27.29 (41.62) 32.67 (51.89) 5.02 (−19.15,27.97) .674  
Peak knee velocity, 
paretic (degrees/s)b
23.33 (34.34) 24.20 (45.62) 1.06 (−18.73,20.38) .915  
Able to walk 28/37 (75.68) 22/31 (70.97) 0.82 (0.27,2.43) .715  
Tibial angle at
x Initial contact −10.78 (4.91) −8.55 (5.98) 2.45 (−0.41,5.31) .092  
x Foot flatb −3.59 (5.14) −2.36 (4.64) 1.27 (−1.58,4.06) .379  
x Midstance 6.48 (5.04) 8.2 (5.33) 1.97 (−1.13,5.06) .208  
x Heel riseb 26.47 (6.12) 27.7 (6.18) 0.88 (−2.71,4.50) .630  
x Terminal contactb 40.76 (8.19) 41.53 (8.45) 0.71 (−3.93,5.35) .764  
x Midswingb 20.00 (8.74) 21.31 (5.67) 0.87 (−2.68,4.80) .647  
Ratio of stance timesb −0.03 (0.07) −0.04 (0.04) .879  
Ratio of step lengths −0.02 (0.14) −0.00 (0.13) .909  
Ratio of peak angular 
velocities
−0.11 (0.20) −0.18 (0.16) .499  
Abbreviations: CPT, conventional physical therapy; FAC, Functional Ambulation Category; MRMI, Modified Rivermead Mobility Index; SD, standard 
deviation; IQR, interquartile range.
aValues are mean (SD), median (IQR), or number (%).
bBootstrap used because of nonnormality of residuals; mean (SD) refer only to those able to walk.
 at University of Strathclyde on August 27, 2015nnr.sagepub.comDownloaded from 
8 Neurorehabilitation and Neural Repair 
(P = .0001) in FAC score from a median of 1 (1-1) to 2 
(1-2).12 However, the earlier trial had a greater risk of poten-
tial bias than the one reported here for the following reasons: 
randomization was not to group but to the order of each indi-
vidual using an AFO once the control walk (without AFO) 
had been made; observers were not masked to conditions 
because participants used the AFO during testing sessions; 
and an independent randomization service was not used. For 
the present trial, bias protection was also provided by adher-
ing to the intention-to-treat principle and reporting all planned 
outcomes. This trial evaluated a highly visible SWIFT Cast; 
therefore, it was not possible to mask research therapists, par-
ticipants, or clinical staff to the allocated intervention.
The 2 trials also differed in regard to the purpose of the 
devices and their use during outcome measures. The earlier 
trial evaluated the immediate effects on walking of an off-
the-shelf plastic AFO to compensate for motor impair-
ment,12 whereas the present trial evaluated the potential 
restorative effect on motor function of using an individually 
fitted SWIFT Cast over a 6-week period. It is possible that 
had measurements been collected while wearing a SWIFT 
Cast, walking improvement could have been detected. 
However, that was not the focus of the present trial because 
(a) it is already known that the immediate effects are posi-
tive both early and later after stroke11 and (b) the focus of 
rehabilitation in the first 3 months after stroke is to restore 
function rather than compensate for its loss.13
There is a possibility of differential response for sub-
groups of stroke survivors to the same intervention. For 
example, robotic gait training may be better than routine 
therapy for people early after stroke (mean 20 days) if they 
have low ability to voluntarily contract paretic muscle but 
not if they have high ability.14 This possibility is being 
tested through the indicators of response analysis of the 
embedded study of the present trial.5
That the present trial found no difference between the 
groups does not generalize to all types of AFOs. For exam-
ple, stroke survivors walked further and negotiated stairs 
faster using a dynamic AFO than a carbon-composite 
AFO.15 It is possible, therefore, that an AFO custom-made 
by an orthotist for individuals early after stroke would 
restore motor function to a higher level than CPT alone. 
This hypothesis requires testing.
Another possible influence on these results is that insuf-
ficient walking training was undertaken to utilize better bio-
mechanical alignment enabled by the SWIFT Cast. Intensity 
of training is known to be an important principle of neural 
plasticity,16 and there could be a critical threshold for effi-
cacy.17 Both groups in this trial received essentially the same 
amount of CPT and walking training. Further investigation 
could determine the critical threshold for the number of step-
ping repetitions during walking wearing a SWIFT Cast.
The sample size for this trial was estimated by a power 
calculation informed by data from a group of similar stroke 
survivors receiving the same CPT as in this trial.18 However, 
the actual sample size was less than planned: 105 of 120 
participants (87.5%). Published reports of earlier trials of 
lower-limb interventions early after stroke are scarce,19 
which hinders direct comparison, but recruitment compares 
well with the finding that 78% of funded trials recruit to 
80% of their target.20
An important strength of the trial reported here is that, on 
average, participants were recruited 20.8 days after stroke. 
Early rehabilitation is recommended because of potential 
for brain reorganization.20 In clinical practice, the majority 
of rehabilitation is provided in this time period, and yet 
most rehabilitation trials are conducted later in recovery.19
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